The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
MEBEVERINE GPPL, MEBEVERINE GXP, CMEBEVERINE, COLOBEVERINE, COLOVERINE, CVERINE, MEBERINE (Generic Partners Pty Ltd)
Product name
MEBEVERINE GPPL, MEBEVERINE GXP, CMEBEVERINE, COLOBEVERINE, COLOVERINE, CVERINE, MEBERINE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
167 working days (255)
Active ingredients
Mebeverine hydrochloride
Registration type
New generic medicine
Indication
MEBEVERINE GPPL, MEBEVERINE GXP, CMEBEVERINE, COLOBEVERINE, COLOVERINE, CVERINE, MEBERINE (tablets) is indicated in the management of the irritable bowel syndrome ('irritable colon', 'spastic colon', functional bowel disorders', spastic constipation', 'nervous diarrhoea'). Mebeverine hydrochloride is used to treat the symptoms of this condition - i.e. abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.